SARMs vs peptides — what the legal and pharmacological difference actually is
SARMs and peptides are two adjacent product categories that share vendor catalogues but have distinct chemistry, pharmacology, and US legal status. Understanding the difference matters: a research peptide is generally outside DEA scheduling, while several SARMs are scheduled at the state level (California, others) and pending federal scheduling proposals. Vendors who sell both — and there are several — bring SARM regulatory attention onto their peptide catalogues.
A SARM is a small-molecule drug that selectively binds the androgen receptor. Examples: Ostarine (MK-2866), Cardarine (GW-501516), Andarine (S4), RAD-140 (Testolone), LGD-4033 (Ligandrol), YK-11. SARMs were developed by pharmaceutical companies as candidate treatments for osteoporosis, sarcopenia, and androgen deficiency; none have completed FDA approval for human therapeutic use. They are sold as research chemicals in the same channel as peptides but operate via a different pharmacological mechanism (receptor binding) and a different chemical class (small molecules, not amino-acid chains).
A peptide is a short chain of amino acids. Examples relevant to the research market: BPC-157, TB-500, GHK-Cu, Selank, Semax, Epithalon, PT-141, Tesamorelin, CJC-1295. Peptides act through receptor binding, enzyme modulation, or signalling cascades depending on the specific molecule. Most research peptides are not scheduled by the DEA federally; most are also not scheduled by states. The FDA has approved a handful of peptides as drugs (Tesamorelin as Egrifta for HIV-associated lipodystrophy, etc) but those approved formulations are not what research vendors sell.
On US legal status, the meaningful divergence is at the state level. California scheduled certain SARMs (Ostarine, LGD-4033) under a 2022 law focused on athletic-enhancement compounds; Indiana, Tennessee, and a handful of other states have similar postures. The DEA has not federally scheduled any of the major SARMs as of this writing — but a 2018 federal proposal (the SARMs Control Act, never passed) and ongoing FDA warning letters about SARMs in dietary supplements indicate continued regulatory interest.
Most research peptides are not similarly scheduled. BPC-157, TB-500, and the other commonly traded peptides are not on any federal or state schedule. The exceptions are peptide-class compounds that have been federally scheduled under different names — e.g., synthetic cannabinoid analogues that are not technically peptides but get conflated. This is rare for the BPC-157 / TB-500 / GHK-Cu set the typical research vendor sells.
For vendor selection, the practical implication is that vendors who specialize in peptides only (Core Peptides, Particle Peptides, Peptide Pros) have a cleaner regulatory profile than vendors who sell both peptides and SARMs (SwissChems, Behemoth Labz, Direct SARMs). The dual-catalogue vendors are not illegal — they comply with research-use-only labelling — but they attract more regulatory attention because of the SARM catalogue, and that attention can spill onto the peptide product line.
For US researchers buying for legitimate research, the simpler path is peptide-only vendors when the research scope only needs peptides. The dual-catalogue vendors are appropriate when the research scope explicitly needs SARMs and the researcher has confirmed the SARMs in question are not state-scheduled in their jurisdiction. PeptideGuide does not currently track SARM listings; we focus on the peptide catalogue and flag dual-catalogue status in vendor reviews.
On WADA / sport-doping side, SARMs are squarely on the WADA Prohibited List under S1.2 (other anabolic agents) and have been responsible for a meaningful share of athlete sanctions over the past decade. Peptides span multiple WADA categories: BPC-157 is on the Prohibited List under S0 (non-approved substances) since 2022, growth-hormone secretagogues are under S2, etc. Athletes in tested sports should treat both categories with extreme caution and consult their anti-doping authority.
✓Pros
- Distinct classes — researchers can pick a peptide-only vendor for cleaner regulatory profile
- Most research peptides are not federally or state scheduled
- Dual-catalogue vendors offer wider product range when SARMs are explicitly needed
×Cons
- SARMs are state-scheduled in CA + others; researchers must verify state law
- Dual-catalogue vendors carry regulatory attention that can spill onto peptide lines
- WADA prohibits SARMs (S1.2) and many peptides (S0 / S2) — tested athletes must avoid both
Are SARMs legal in the US?
Federally, SARMs are not approved as drugs and not scheduled by the DEA, so they exist in the same research-chemical grey zone as peptides. State law varies: California scheduled Ostarine and LGD-4033 in 2022; Indiana and Tennessee have similar laws. Buying state-scheduled SARMs in those states is illegal regardless of the federal posture.
Are peptides legal in the same way?
Most research peptides are not state-scheduled anywhere and not federally scheduled. They sit in a cleaner regulatory zone than SARMs. Specific peptides may be regulated locally (some hormone-secretagogue analogues), so researchers should verify any specific compound, but BPC-157, TB-500, GHK-Cu, Selank, Semax, and the other typical research peptides are generally unscheduled.
Why do some vendors sell both SARMs and peptides?
Customer overlap. The biohacker / athletic-research demographic that buys peptides often also wants SARMs, and the operational cost of running both catalogues is small. SwissChems, Behemoth Labz, and Direct SARMs are the better-known dual-catalogue vendors. Peptide-only vendors include Core Peptides, Particle Peptides, and Peptide Pros.
Does buying peptides from a SARM-selling vendor put me at legal risk?
For the buyer, generally no — the legal status of each individual compound is what matters, not the catalogue mix. Buying a research peptide from a vendor who also sells SARMs does not turn the peptide into a SARM. For the vendor, the dual catalogue carries higher regulatory attention and a higher chance of enforcement action that could disrupt the entire catalogue. That is why some researchers prefer peptide-only vendors for supply continuity.
What about WADA-banned status?
For tested athletes, the answer is to avoid both. SARMs are squarely on the WADA Prohibited List under S1.2. Peptides are scattered: BPC-157 is on S0 (non-approved substances) since 2022, GH secretagogues are S2, etc. The WADA Prohibited List 2026 is the authoritative document; tested athletes should consult their anti-doping authority before any research-chemical use.
Has the federal government tried to schedule SARMs?
Yes, multiple times. The 2018 SARMs Control Act was proposed but never passed. The FDA has issued multiple warning letters to companies selling SARMs in dietary supplements (which is a separate issue from research-chemical sales). The DEA has not federally scheduled the major SARMs as of this writing, but the regulatory direction is toward more restriction, not less.